Fragment-based lead discovery using X-ray crystallography.
暂无分享,去创建一个
Christopher W Murray | Michael J Hartshorn | C. Murray | M. Hartshorn | H. Jhoti | I. Tickle | Harren Jhoti | Martyn Frederickson | Anne Cleasby | M. Frederickson | Ian J Tickle | A. Cleasby
[1] Paul Greengard,et al. Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.
[2] L Meijer,et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. , 1999, Pharmacology & therapeutics.
[3] Youwei Yan,et al. Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. , 2003, Bioorganic & medicinal chemistry letters.
[4] J. Pflugrath,et al. The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.
[5] G. Bemis,et al. Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding , 2002, Proteins.
[6] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[7] E. Mandine,et al. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. , 2003, Journal of medicinal chemistry.
[8] S F Campbell,et al. Science, art and drug discovery: a personal perspective. , 2000, Clinical science.
[9] Johan Schultz,et al. Structure-based screening and design in drug discovery. , 2002, Drug discovery today.
[10] Christopher W Murray,et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.
[11] Jean M. Severin,et al. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.
[12] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[13] Jean-Pierre Marquette,et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.
[14] Andrew J. Sharff. HIGH THROUGHPUT CRYSTALLOGRAPHY ON AN IN-HOUSE SOURCE, USING ACTOR , 2003 .
[15] G. Bemis,et al. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. , 1999, Current medicinal chemistry.
[16] S. Kim,et al. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. , 1996, Journal of medicinal chemistry.
[17] P J Thomas,et al. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. , 1999, Biochemistry.
[18] S. Brady,et al. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.
[19] K. Acharya,et al. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution. , 1997, Biochemistry.
[20] D. Kostrewa,et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.
[21] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[22] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[23] T R Burke,et al. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. , 1998, Biochemistry.
[24] Karl A. Walter,et al. ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .
[25] J. Maraganore,et al. Thrombin structure and function: why thrombin is the primary target for antithrombotics. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[26] Protein-Ligand Interactions,et al. Knowledge-based Scoring Function to Predict , 2000 .
[27] R. Murray. Molecular recognition. , 2009, Analytical Chemistry.
[28] D. Zaller,et al. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. , 2003 .
[29] J. Gasteiger,et al. Automatic generation of 3D-atomic coordinates for organic molecules , 1990 .
[30] D. E. Clark,et al. Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.
[31] Ajay,et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.
[32] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[33] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[34] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[35] R. Stroud,et al. Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Bitonti,et al. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. , 2001, Journal of medicinal chemistry.
[37] Paul Watson,et al. A web-based platform for virtual screening. , 2003, Journal of molecular graphics & modelling.
[38] E. Goldsmith,et al. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Greer,et al. Automated crystal mounting and data collection for protein crystallography. , 2000, Structure.
[40] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[41] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[42] D. Lane,et al. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. , 2000, Current medicinal chemistry.
[43] Tudor I. Oprea,et al. The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.
[44] Bin Ye,et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. , 2002, Biochemistry.
[45] Dustin J Maly,et al. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] Elizabeth J. Goldsmith,et al. Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket* , 1998, The Journal of Biological Chemistry.
[47] G. Bemis,et al. Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.
[48] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[49] L. Iversen,et al. 2-(Oxalylamino)-Benzoic Acid Is a General, Competitive Inhibitor of Protein-tyrosine Phosphatases* , 2000, The Journal of Biological Chemistry.
[50] T. J. R. Harris. High throughput X-ray crystallography for Drug Discovery , 2000 .
[51] B. Kennedy,et al. Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. , 2001, Journal of medicinal chemistry.
[52] Johan Schultz,et al. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. , 2002, Journal of the American Chemical Society.
[53] N. Tonks,et al. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. , 1991, Science.
[54] Tudor I. Oprea,et al. Is There a Difference Between Leads and Drugs? A Historical Perspective. , 2001 .
[55] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[56] L. Vitagliano,et al. Productive and nonproductive binding to ribonuclease A: X‐ray structure of two complexes with uridylyl(2′,5′)guanosine , 2000, Protein science : a publication of the Protein Society.
[57] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[58] A V Finkelstein,et al. The price of lost freedom: entropy of bimolecular complex formation. , 1989, Protein engineering.
[59] Michael J Hartshorn,et al. AstexViewer: a visualisation aid for structure-based drug design. , 2002, Journal of computer-aided molecular design.
[60] H. Jhoti,et al. Structure-based screening of low-affinity compounds. , 2002, Drug discovery today.
[61] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[62] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.